Cover ImageSALE
市場調查報告書

移植物抗宿主病 (GVHD) 治療藥的全球市場:2017年∼2021年

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 544339
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
移植物抗宿主病 (GVHD) 治療藥的全球市場:2017年∼2021年 Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021
出版日期: 2017年08月16日 內容資訊: 英文 78 Pages
簡介

全球移植物抗宿主病 (GVHD) 治療藥市場在2017年到2021年間,預測將以7.15%的年複合成長率 (CAGR) 擴大。

本報告依地區別提供全球移植物抗宿主病 (GVHD) 治療藥市場現狀分析與今後預測,再加上市場成長因素與課題,主要趨勢,主要企業簡介等資訊。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 簡介

第5章 疾病概要

第6章 市場概要

  • 波特的五力分析

第7章 開發平台形勢

第8章 各疾病類型的市場分類

  • 急性移植物抗宿主病

第9章 地理區分

  • 南北美洲
  • 歐洲·中東·非洲地區
  • 亞太地區

第10章 決策架構

第11章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭模式

第14章 主要供應商分析

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • 其他卓越供應商

第15章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR14217

About Graft vs Host Disease (GVHD) Treatment

Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.

Technavio's analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • Abbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte

Market driver

  • Increased prevalence of cancer
  • For a full, detailed list, view our report

Market challenge

  • Off-label use of drugs
  • For a full, detailed list, view our report

Market trend

  • Inorganic growth strategies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market overview

  • Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type

  • Acute GVHD

PART 09: Geographical segmentation

  • GVHD treatment market in Americas
  • GVHD treatment market in EMEA
  • GVHD treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Inorganic growth strategies
  • Newer applications of bone marrow transplant
  • Growing focus toward the use of biologics

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Mechanism of GVHD
  • Exhibit 02: Global GVHD treatment market growth promoters
  • Exhibit 03: Major acute GVHD symptoms
  • Exhibit 04: Major chronic GVHD symptoms
  • Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis in global GVHD treatment market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline molecules as per vendors
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016
  • Exhibit 11: Symptoms in acute GVHD
  • Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions)
  • Exhibit 13: Symptoms in chronic GVHD
  • Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions)
  • Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021
  • Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
  • Exhibit 17: Market scenario in Americas
  • Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in EMEA
  • Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in APAC
  • Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions)
  • Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016)
  • Exhibit 24: Various major types of cancers managed by bone marrow transplant
  • Exhibit 25: Various off-label drugs used in the management of GVHD
  • Exhibit 26: Various symptoms and disorders associated with GVHD
  • Exhibit 27: Legal and ethical issues in countries
  • Exhibit 28: Inorganic growth strategies
  • Exhibit 29: Newer applications of bone marrow transplant
  • Exhibit 30: Competitive structure analysis of global GVHD treatment market 2016
  • Exhibit 31: Market penetration of various GVHD drugs manufacturers worldwide 2016
  • Exhibit 32: Strategic success factors of companies in global GVHD treatment market
  • Exhibit 33: Bristol-Myers Squibb: Key highlights
  • Exhibit 34: Bristol-Myers Squibb: Strength assessment
  • Exhibit 35: Bristol-Myers Squibb: Strategy assessment
  • Exhibit 36: Bristol-Myers Squibb: Opportunity assessment
  • Exhibit 37: F. Hoffmann-La Roche: Key highlights
  • Exhibit 38: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 39: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 40: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 41: Novartis: Key highlights
  • Exhibit 42: Novartis: Strength assessment
  • Exhibit 43: Novartis: Strategy assessment
  • Exhibit 44: Novartis: Opportunity assessment
  • Exhibit 45: Pfizer: Key highlights
  • Exhibit 46: Pfizer: Strength assessment
  • Exhibit 47: Pfizer: Strategy assessment
  • Exhibit 48: Pfizer: Opportunity assessment
Back to Top